About
Brian Goff joined Agios as chief executive officer and a member of the board of directors in August 2022. He has more than 30 years of experience in the biopharmaceutical industry, and for the past decade has been an executive global leader focused on rare diseases.
Previously, he was executive vice president, chief commercial and global operations officer of Alexion Pharmaceuticals until its acquisition by AstraZeneca in 2021, where he led worldwide commercial and country operations as well as global manufacturing and product supply. Before Alexion, he was chief operating officer and a board member of Neurovance, which was acquired by Otsuka Pharmaceuticals in 2017, and prior to that served as Baxalta's executive vice president and president of the hematology division until Shire Pharmaceuticals acquired Baxalta in 2016.
He holds an MBA from the Wharton School at the University of Pennsylvania and a Bachelor of Arts from Skidmore College.
Roles
Agios Pharmaceuticals, Inc.
Chief Executive Officer and Director · Current role
Aug 2022–present
Alexion Pharmaceuticals
EVP, Chief Commercial and Global Operations Officer · Led global commercial and operations teams across North America, EMEA, Japan, Asia Pacific and Latin America.
Jun 2017 – Jul 2021
Neurovance
Chief Operating Officer and Director · Served until the company's acquisition by Otsuka Pharmaceutical.
Dec 2016 – Mar 2017
Baxalta
EVP & President – Hematology Division · Served until the company's acquisition by Shire.
Jan 2015 – Jul 2016
Baxter Healthcare
Global Hemophilia Franchise Head
Jun 2012 – Dec 2014
Novartis Pharmaceuticals / Johnson & Johnson
Sales and marketing roles of increasing responsibility · Earlier-career commercial roles.
—
Alexion Pharmaceuticals
Executive Vice President, Chief Commercial and Global Operations Officer · Led worldwide commercial and country operations plus global manufacturing and product supply, until the company's acquisition by AstraZeneca in 2021.
—
Neurovance
Chief Operating Officer and board member · Venture-backed company acquired by Otsuka Pharmaceuticals in 2017.
—
Baxalta
Executive Vice President and President, Hematology Division · Served until Shire Pharmaceuticals acquired Baxalta in 2016.
—
External Roles
Intellia Therapeutics
Director; chair of compensation and talent development committee
—
Fixed Compensation
FY 2025
All other compensation
$11,789
Performance Compensation
Data from FY 2025
Cash incentive
Non-equity incentive plan compensation
$592,804
Stock awards
Also at Agios Pharmaceuticals, Inc.